A Cost-Effectiveness Analysis of Pasireotide Long-Acting Compared To Continued Use of A First-Line Somatostatin Antagonist For The Treatment of Acromegaly In Sweden
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1408
https://www.valueinhealthjournal.com/article/S1098-3015(16)32774-7/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1324
First Page :
A591
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32774-7&doi=10.1016/j.jval.2016.09.1408